Intangible Assets

Abbott’s brands in diagnostics, diabetes care, and nutrition support repeat purchasing and clinician familiarity, which sustains pricing power better than smaller peers with less trusted portfolios.

Its regulated medical-device and diagnostics franchises benefit from FDA/CE clearances and clinical evidence requirements, which raise entry barriers versus generic consumer-health competitors.

The company’s broad installed base across hospitals, labs, and home-use products reinforces product credibility and channel access, making displacement harder than for single-category peers.

Compared with peers such as Medtronic and Becton Dickinson, Abbott’s moat is less dependent on one product line because its intangible assets are diversified across multiple healthcare end markets.

Switching Costs

Abbott’s continuous glucose monitoring and diagnostics workflows create operational switching friction because patients, clinicians, and labs must retrain, revalidate, and re-integrate systems to change vendors.

In diabetes care, sensor ecosystems and app-based monitoring increase retention versus commodity device peers because users value continuity of data and care routines.

In diagnostics, installed instruments, assay validation, and lab workflow integration make replacement costly and time-consuming, which supports stickier revenue than in less integrated healthcare supply businesses.

Compared with peers like Dexcom and Roche Diagnostics, Abbott’s switching costs are strong but not absolute because customers can still adopt alternative platforms when pricing, reimbursement, or clinical preference changes.

Network Effects

Abbott’s connected diabetes and digital health ecosystems improve product utility as more users and clinicians generate data, but the effect is narrower than true platform network effects.

More patient and clinician usage can improve app engagement and care continuity, which modestly strengthens retention versus standalone device peers.

Its diagnostics and nutrition businesses do not exhibit strong cross-side network effects because customer value is driven more by product performance and reimbursement than by user-to-user interaction.

Compared with platform-like healthcare software peers, Abbott’s network effects are present but limited, so they support the moat rather than define it.

Cost Advantage

Abbott’s scale in manufacturing, procurement, and global distribution lowers unit costs relative to smaller peers, which helps protect margins in commoditizing categories.

Its diversified portfolio spreads R&D and regulatory costs across multiple franchises, improving cost absorption versus narrower competitors.

The company’s ROIC of about 6.1% and ROCE of about 8.7% indicate acceptable but not exceptional capital efficiency, suggesting cost advantage exists but is not dominant.

Compared with peers such as Medtronic, Becton Dickinson, and Dexcom, Abbott likely has a meaningful cost position, but it does not appear to have a structurally superior low-cost model across all segments.

Efficient Scale

Abbott operates in regulated healthcare niches where scale in clinical evidence, manufacturing quality, and global distribution can deter smaller entrants and support durable share.

Its presence across diagnostics, diabetes care, and nutrition gives it enough breadth to compete efficiently in multiple submarkets without relying on a single monopoly-like position.

The company benefits from large installed bases and recurring consumables, which make it harder for smaller peers to win share purely on price.

Compared with peers, Abbott has strong efficient scale in several categories, but the markets remain contestable enough that the advantage is durable rather than exclusive.

Overall Score

Abbott has a strong, diversified moat driven mainly by switching costs, regulated intangible assets, and efficient scale, with moderate network effects and a solid but not dominant cost position versus peers.